ARMR Sciences Achieves Major Milestone Toward Overdose Protection, Produces First-Ever Anti-Fentanyl Immune Response in Humans

Interim phase 1/2 data confirm significant anti-fentanyl antibody production at the lowest dose, with a well-tolerated safety profile across all patients dosed. NEW YORK, June 17, 2026 /PRNewswire/ -- ARMR Sciences, a clinical-stage biodefense company developing a platform of medical...